TITLE

Novel obesity drugs, oncology biosimilars to impact markets

PUB. DATE
October 2009
SOURCE
PharmacoEconomics & Outcomes News;10/3/2009, Issue 588, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the statement by Decision Resources that by 2018, obesity drug market is expected to grow more than six times and biosimilars are expected to erode sales of three branded oncology drugs. According to this report, biosimilars of the oncology drugs rituximab, cetuximab and trastuzumab are expected to erode 8.2 billion U.S. dollars in sales in Europe and in the U.S. Medications that are expected to capture 87% of total obesity market in 2018 include lorcaserin and pramlintide/leptin combination therapies.
ACCESSION #
44604307

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics